What does BCMA CAR-T cell therapy involve?

This therapy begins with collecting your own T cells through apheresis. These cells are genetically engineered in a laboratory to express a chimeric antigen receptor (CAR) targeting BCMA, a protein on myeloma cells. After a short conditioning chemotherapy to reduce existing immune cells, the modified CAR-T cells are infused back into your bloodstream. They then seek out and destroy BCMA-positive myeloma cells. The entire process, from cell collection to infusion, typically takes 3–4 weeks in a specialized oncology center.